- Conditions
- Retinoblastoma
- Interventions
- filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, topotecan hydrochloride, autologous bone marrow transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 15 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2005
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,602
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Retinopathy of Prematurity
- Interventions
- Trans-scleral Cryotherapy
- Procedure
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Up to 1 Year
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1986 – 2003
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 20 more
- Conditions
- Age Related Macular Degeneration, Geographic Atrophy
- Interventions
- Not listed
- Lead sponsor
- Carl Zeiss Meditec, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Oakland, California • Jackson, Michigan
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Brolucizumab 6 mg, Panretinal photocoagulation laser
- Biological · Procedure
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Beverly Hills, California • Fullerton, California + 32 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- human retinal progenitor cells, Mock injection
- Biological · Other
- Lead sponsor
- jCyte, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Irvine, California • Los Angeles, California • Boston, Massachusetts
- Conditions
- Age-related Macular Degeneration
- Interventions
- E10030
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Retinal Diseases, Stargardt's Disease, Retinitis Pigmentosa
- Interventions
- Not listed
- Lead sponsor
- Retina Institute of Hawaii
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 4
- States / cities
- Hilo, Hawaii • Honolulu, Hawaii • Kahului, Hawaii + 1 more
- Conditions
- Geographic Atrophy
- Interventions
- ORACEA®, Placebo
- Drug
- Lead sponsor
- Paul Yates, MD, PhD
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 37
- States / cities
- Glendale, California • Poway, California • Golden, Colorado + 31 more
- Conditions
- Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes, Diabetes, Retinopathy, Neuropathy, Nephropathy, Blood Pressure, Cardiovascular Risk, Microvascular
- Interventions
- observational study
- Other
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Exudative Macular Degeneration
- Interventions
- TRIPLE COMBINATION THERAPY
- Procedure
- Lead sponsor
- The Retina Center of St. Louis County, PC
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Age-Related Macular Degeneration, Neovascularization, Choroidal
- Interventions
- Not listed
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 73 participants
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Retinitis Pigmentosa
- Interventions
- Not listed
- Lead sponsor
- Second Sight Medical Products
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Denver, Colorado • Miami, Florida + 13 more
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
- Interventions
- Biological Sample Collection
- Other
- Lead sponsor
- New York Stem Cell Foundation Research Institute
- Other
- Eligibility
- 30 Days and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2045
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cardiovascular Autonomic Neuropathy, Diabetic Autonomic Neuropathy, Autonomic Dysfunction
- Interventions
- ANSAR ANX 3.0 Software
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Age-related Macular Degeneration
- Interventions
- VMS diary booklet, Standard of Care
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- Not listed
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Macular Degeneration
- Interventions
- Rheopheresis blood filtration
- Device
- Lead sponsor
- OccuLogix
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2005
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Coral Gables, Florida • Fort Myers, Florida + 4 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- Not listed
- Lead sponsor
- MeiraGTx UK II Ltd
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 6
- States / cities
- La Jolla, California • Stanford, California • Atlanta, Georgia + 3 more
- Conditions
- Cerebral Small Vessel Diseases, Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, Cerebral Microbleeding, Sporadic White Matter Disease
- Interventions
- Cilostazol
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Macular Degeneration
- Interventions
- Lutein
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 60 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetic Retinopathy
- Interventions
- blood draw
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 21 Years to 98 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Epiretinal Membrane
- Interventions
- Immediate Vitrectomy, Deferred Vitrectomy
- Procedure
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 47
- States / cities
- Scottsdale, Arizona • Glendale, California • Huntington Beach, California + 41 more
- Conditions
- Geographic Atrophy
- Interventions
- Lampalizumab, Sham
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 906 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
- Conditions
- Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
- Interventions
- ALK-001, Placebo
- Drug
- Lead sponsor
- Alkeus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 8 Years to 70 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 11 more